KR20100039331A - 치료용 피라졸로퀴놀린 유도체 - Google Patents

치료용 피라졸로퀴놀린 유도체 Download PDF

Info

Publication number
KR20100039331A
KR20100039331A KR1020107000330A KR20107000330A KR20100039331A KR 20100039331 A KR20100039331 A KR 20100039331A KR 1020107000330 A KR1020107000330 A KR 1020107000330A KR 20107000330 A KR20107000330 A KR 20107000330A KR 20100039331 A KR20100039331 A KR 20100039331A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
pharmaceutically acceptable
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107000330A
Other languages
English (en)
Korean (ko)
Inventor
아란 피. 카프란
바르샤 굽타
얀 더블유.에프. 웨슬리
Original Assignee
헬리콘 테라퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬리콘 테라퓨틱스 인코퍼레이티드 filed Critical 헬리콘 테라퓨틱스 인코퍼레이티드
Publication of KR20100039331A publication Critical patent/KR20100039331A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020107000330A 2007-06-08 2008-06-06 치료용 피라졸로퀴놀린 유도체 Withdrawn KR20100039331A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94300507P 2007-06-08 2007-06-08
US60/943,005 2007-06-08

Publications (1)

Publication Number Publication Date
KR20100039331A true KR20100039331A (ko) 2010-04-15

Family

ID=40096440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107000330A Withdrawn KR20100039331A (ko) 2007-06-08 2008-06-06 치료용 피라졸로퀴놀린 유도체

Country Status (13)

Country Link
US (2) US7872002B2 (enExample)
EP (1) EP2166852B1 (enExample)
JP (1) JP2010529143A (enExample)
KR (1) KR20100039331A (enExample)
CN (1) CN101742908A (enExample)
AT (1) ATE544344T1 (enExample)
AU (1) AU2008261884A1 (enExample)
BR (1) BRPI0812366A2 (enExample)
CA (1) CA2688395A1 (enExample)
ES (1) ES2386168T3 (enExample)
IL (1) IL202270A0 (enExample)
MX (1) MX2009013202A (enExample)
WO (1) WO2008154438A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2483728T3 (es) * 2007-06-08 2014-08-07 Dart Neuroscience (Cayman) Ltd Derivados terapéuticos de pirazolonafatiridina
ES2386168T3 (es) * 2007-06-08 2012-08-10 Helicon Therapeutics, Inc. Derivados de pirazoloquinolina terapéuticos
US7863266B2 (en) * 2007-06-08 2011-01-04 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2017085053A1 (en) 2015-11-16 2017-05-26 Fundación Para La Investigación Médica Aplicada Novel compounds as inhibitors of dna methyltransferases
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
CN116390923B (zh) * 2020-08-21 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5334595A (en) * 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
GB9716347D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) * 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
ATE425164T1 (de) 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
AR045689A1 (es) 2003-05-29 2005-11-09 Millennium Pharm Inc Compuestos derivados de 2,5-dihidro-pirazolo[4,3-c]quinolin-4-ona como inhibidores de chk-1 y composiciones farmaceuticas que los contienen
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2006287378A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
JP2008047893A (ja) * 2006-08-11 2008-02-28 Samsung Electronics Co Ltd 薄膜トランジスタ表示板及びその製造方法
ES2386168T3 (es) * 2007-06-08 2012-08-10 Helicon Therapeutics, Inc. Derivados de pirazoloquinolina terapéuticos

Also Published As

Publication number Publication date
CN101742908A (zh) 2010-06-16
JP2010529143A (ja) 2010-08-26
ATE544344T1 (de) 2012-02-15
AU2008261884A1 (en) 2008-12-18
EP2166852A1 (en) 2010-03-31
ES2386168T3 (es) 2012-08-10
IL202270A0 (en) 2010-06-16
BRPI0812366A2 (pt) 2016-08-02
EP2166852B1 (en) 2012-02-08
US20110065693A1 (en) 2011-03-17
HK1142775A1 (en) 2010-12-17
US8598159B2 (en) 2013-12-03
US7872002B2 (en) 2011-01-18
MX2009013202A (es) 2010-04-09
US20080306049A1 (en) 2008-12-11
EP2166852A4 (en) 2010-07-07
WO2008154438A1 (en) 2008-12-18
CA2688395A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
US8343957B2 (en) Therapeutic pyrazoloquinoline urea derivatives
US8598159B2 (en) Therapeutic pyrazoloquinoline derivatives
US8497262B2 (en) Therapeutic pyrazolonaphthyridine derivatives
JP2010529145A5 (enExample)
HK1142775B (en) Therapeutic pyrazoloquinoline derivatives
HK1142496B (en) Therapeutic pyrazoloquinoline urea derivatives
US9012470B2 (en) Therapeutic 5,6,5-tricyclic analogs
HK1142776A (en) Therapeutic pyrazoloquinoline urea derivatives
HK1144891A (zh) 治疗用吡唑并喹啉衍生物
HK1142774B (en) Therapeutic pyrazolonaphthyridine derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid